Related Experiment Videos
Cytochemical "normal" and "abnormal" eosinophils in acute leukemias
American Journal of Hematology
|January 1, 1977
Summary
Abnormal eosinophils in acute leukemias exhibit distinct cytochemical features. These findings aid in differentiating normal from abnormal eosinophils, crucial for leukemia diagnosis.
Area of Science:
- Hematology
- Cell Biology
Background:
- Eosinophils are key leukocytes involved in various disorders, including acute leukemias.
- Morphological assessment of eosinophils is often insufficient for distinguishing normal from abnormal cells.
Purpose of the Study:
- To identify specific cytochemical criteria for differentiating normal and abnormal eosinophils in acute leukemias.
- To investigate the utility of cytochemistry in evaluating eosinophilic cell abnormalities in leukemic conditions.
Main Methods:
- Defined 'normal' eosinophil cytochemistry based on specific enzyme and staining reactions (peroxidase, esterase, Sudan black, PAS, etc.).
- Analyzed cytochemical profiles of eosinophils in seven acute leukemia cases (two acute myeloblastic, five myelomonocytic).
- Compared cytochemical findings in leukemic eosinophils against established 'normal' criteria.
Main Results:
- Normal eosinophils typically lack alkaline phosphatase, chloroacetate esterase, toluidine blue metachromasia, Astra blue positivity, and specific PAS-positive granules.
- Abnormal eosinophils in acute leukemias demonstrated chloroesterase activity, PAS and Astra blue positivity in specific granules, toluidine blue metachromasia, and variable cyanide-resistant peroxidase activity.
- Significant deviations from normal cytochemical profiles were observed in leukemic eosinophils.
Conclusions:
- Cytochemical analysis provides valuable criteria for identifying abnormal eosinophils in acute leukemias.
- These cytochemical differences can aid in the diagnostic evaluation of eosinophilic abnormalities in leukemia.
- Cytochemistry offers a more objective method than morphology alone for assessing eosinophil status in leukemic patients.